Literature DB >> 23237130

Modifiable factors associated with failure to attain low-density lipoprotein cholesterol goal at 6 months after acute myocardial infarction.

Seth S Martin1, Kensey Gosch, Krishnaji R Kulkarni, John A Spertus, Robin Mathews, P Michael Ho, Thomas M Maddox, L Kristin Newby, Karen P Alexander, Tracy Y Wang.   

Abstract

BACKGROUND: Although controversial, reducing low-density lipoprotein cholesterol (LDL-C) to target levels remains a common therapeutic goal after acute myocardial infarction (AMI). We sought to illuminate patient and provider characteristics associated with LDL-C goal nonattainment after AMI.
METHODS: In an observational registry of 24 US hospitals, we included 366 patients with AMI who had baseline LDL-C levels ≥100 mg/dL and underwent 6-month fasting LDL-C reassessment. Our primary outcome was failure to reach the guideline-recommended LDL-C goal of <100 mg/dL at 6 months post-AMI.
RESULTS: One in 3 patients with AMI with initially elevated LDL-C failed to attain LDL-C goal at 6 months. Compared with those who attained LDL-C goal, those who did not were more often discharged without a statin (21% vs 9%, P < .001), despite only 4% having documented contraindications. Patients not achieving LDL-C goal also more frequently discontinued statin use by 6 months (24% vs 6%, P < .001). Multivariable modeling (c index, 0.78) revealed the absence of a statin prescription at discharge and lack of persistence on statin therapy as the strongest independent factors associated with failure to reach LDL-C goal. Additional independent risk factors were patient report of not consistently adhering to prescribed medications, not participating in cardiac rehabilitation, nonwhite race, and lack of insurance.
CONCLUSIONS: One-third of patients with AMI with baseline hyperlipidemia do not attain the LDL-C goal of <100 mg/dL at 6 months. Our findings support targeted interventions in the transition of AMI care to promote affordable statin prescription at discharge, medication persistence and adherence, and cardiac rehabilitation participation.
Copyright © 2013 Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23237130      PMCID: PMC3607508          DOI: 10.1016/j.ahj.2012.10.005

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  29 in total

1.  Improved treatment of coronary heart disease by implementation of a Cardiac Hospitalization Atherosclerosis Management Program (CHAMP).

Authors:  G C Fonarow; A Gawlinski; S Moughrabi; J H Tillisch
Journal:  Am J Cardiol       Date:  2001-04-01       Impact factor: 2.778

Review 2.  Optimal low-density lipoprotein is 50 to 70 mg/dl: lower is better and physiologically normal.

Authors:  James H O'Keefe; Loren Cordain; William H Harris; Richard M Moe; Robert Vogel
Journal:  J Am Coll Cardiol       Date:  2004-06-02       Impact factor: 24.094

3.  A modified poisson regression approach to prospective studies with binary data.

Authors:  Guangyong Zou
Journal:  Am J Epidemiol       Date:  2004-04-01       Impact factor: 4.897

Review 4.  Cholesterol profile measurement by vertical auto profile method.

Authors:  Krishnaji R Kulkarni
Journal:  Clin Lab Med       Date:  2006-12       Impact factor: 1.935

5.  Lipid-lowering intensification and low-density lipoprotein cholesterol achievement from hospital admission to 1-year follow-up after an acute coronary syndrome event: results from the Medications ApplIed aNd SusTAINed Over Time (MAINTAIN) registry.

Authors:  Chiara Melloni; Bimal R Shah; Fang-Shu Ou; Matthew T Roe; Sidney C Smith; Charles V Pollack; Magnus Ohman; W Brian Gibler; Eric D Peterson; Karen P Alexander
Journal:  Am Heart J       Date:  2010-12       Impact factor: 4.749

6.  The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals.

Authors:  T A Pearson; I Laurora; H Chu; S Kafonek
Journal:  Arch Intern Med       Date:  2000-02-28

7.  Translational Research Investigating Underlying Disparities in Acute Myocardial Infarction Patients' Health Status (TRIUMPH): design and rationale of a prospective multicenter registry.

Authors:  Suzanne V Arnold; Paul S Chan; Philip G Jones; Carole Decker; Donna M Buchanan; Harlan M Krumholz; P Michael Ho; John A Spertus
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2011-07

8.  ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction; A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of patients with acute myocardial infarction).

Authors:  Elliott M. Antman; Daniel T. Anbe; Paul Wayne Armstrong; Eric R. Bates; Lee A. Green; Mary Hand; Judith S. Hochman; Harlan M. Krumholz; Frederick G. Kushner; Gervasio A. Lamas; Charles J. Mullany; Joseph P. Ornato; David L. Pearle; Michael A. Sloan; Sidney C. Smith; Joseph S. Alpert; Jeffrey L. Anderson; David P. Faxon; Valentin Fuster; Raymond J. Gibbons; Gabriel Gregoratos; Jonathan L. Halperin; Loren F. Hiratzka; Sharon Ann Hunt; Alice K. Jacobs; Joseph P. Ornato
Journal:  J Am Coll Cardiol       Date:  2004-08-04       Impact factor: 24.094

9.  Predictors of early discontinuation of evidence-based medicine after acute coronary syndrome.

Authors:  Chiara Melloni; Karen P Alexander; Fang-Shu Ou; Nancy M Allen LaPointe; Matthew T Roe; L Kristin Newby; Khaula Baloch; P Michael Ho; John S Rumsfeld; Eric D Peterson
Journal:  Am J Cardiol       Date:  2009-06-03       Impact factor: 2.778

10.  Does statin therapy initiation increase the risk for myopathy? An observational study of 32,225 diabetic and nondiabetic patients.

Authors:  Gregory A Nichols; Carol E Koro
Journal:  Clin Ther       Date:  2007-08       Impact factor: 3.393

View more
  9 in total

1.  Sex differences in lipid profiles and treatment utilization among young adults with acute myocardial infarction: Results from the VIRGO study.

Authors:  Yuan Lu; Shengfan Zhou; Rachel P Dreyer; Michael Caulfield; Erica S Spatz; Mary Geda; Nancy P Lorenze; Peter Herbert; Gail D'Onofrio; Elizabeth A Jackson; Judith H Lichtman; Héctor Bueno; John A Spertus; Harlan M Krumholz
Journal:  Am Heart J       Date:  2016-10-03       Impact factor: 4.749

Review 2.  Undertreatment or Overtreatment With Statins: Where Are We?

Authors:  Irene García-Fernández-Bravo; Ana Torres-Do-Rego; Antonio López-Farré; Francisco Galeano-Valle; Pablo Demelo-Rodriguez; Luis A Alvarez-Sala-Walther
Journal:  Front Cardiovasc Med       Date:  2022-04-29

3.  Impact of Optimal Medical Therapy in the Dual Antiplatelet Therapy Study.

Authors:  Charles D Resor; Ashwin Nathan; Dean J Kereiakes; Robert W Yeh; Joseph M Massaro; Donald E Cutlip; P Gabriel Steg; Wen-Hua Hsieh; Laura Mauri
Journal:  Circulation       Date:  2016-08-30       Impact factor: 29.690

4.  Changes in low-density lipoprotein cholesterol levels after discharge for acute myocardial infarction in a real-world patient population.

Authors:  Suzanne V Arnold; Mikhail Kosiborod; Fengming Tang; Zhenxiang Zhao; Patrick L McCollam; Julie Birt; John A Spertus
Journal:  Am J Epidemiol       Date:  2014-04-16       Impact factor: 4.897

5.  Risk Factors Associated with Failure to Achieve the Low Density Lipoprotein Cholesterol Therapeutic Target in Patients with Acute Coronary Syndrome: A Longitudinal, Single Centre Investigation.

Authors:  Mojgan Hajahmadi Pourrafsanjani; Ebrahim Khayati Shal; Sina Khezrpour
Journal:  High Blood Press Cardiovasc Prev       Date:  2019-01-25

6.  Factors associated with unattained LDL-cholesterol goals in Chinese patients with acute coronary syndrome one year after percutaneous coronary intervention.

Authors:  Wenduo Zhang; Fusui Ji; Xue Yu; Xinyue Wang
Journal:  Medicine (Baltimore)       Date:  2017-01       Impact factor: 1.889

7.  Clinical Outcomes according to the Achievement of Target Low Density Lipoprotein-Cholesterol in Patients with Acute Myocardial Infarction.

Authors:  Taehoon Ahn; Soon Yong Suh; Kyounghoon Lee; Woong Chol Kang; Seung Hwan Han; Youngkeun Ahn; Myung Ho Jeong
Journal:  Korean Circ J       Date:  2016-11-24       Impact factor: 3.243

Review 8.  Inclisiran: A New Promising Agent in the Management of Hypercholesterolemia.

Authors:  Constantine E Kosmas; Alba Muñoz Estrella; Andreas Sourlas; Delia Silverio; Elizabeth Hilario; Peter D Montan; Eliscer Guzman
Journal:  Diseases       Date:  2018-07-13

9.  The Clinical Outcomes Based on the Achievement of Low-Density Lipoprotein Cholesterol Targets after ST Elevation Myocardial Infarction.

Authors:  Wei-Chieh Lee; Chih-Yuan Fang; Chien-Jen Chen; Cheng-Hsu Yang; Chiung-Jen Wu; Hsiu-Yu Fang
Journal:  J Clin Med       Date:  2019-12-28       Impact factor: 4.241

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.